Aaron Scott

15PUBLICATIONS
125CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.

Robert W Lentz, Julie Lang, Todd M Pitts

|Jul 25, 2025
Unveiling ctDNA Response: Immune Checkpoint Blockade Therapy in a Patient with POLE Mutation-Associated Early-Onset Colon Cancer.

Ramya Ramachandran, Marisa Cannon, Supriya Peshin

|Feb 05, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.

Andrew H Ko, Joseph Chao, Marcus S Noel

|Jan 06, 2025
Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?

Aaron J Scott, Erin B Kennedy, Sepideh Gholami

|Dec 13, 2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.

Rachna T Shroff, Gentry King, Sarah Colby

|Oct 21, 2024
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.

Samuel J Klempner, Mohamad Bassam Sonbol, Zev A Wainberg

Pageof 3

Frequent Collaborators

4 joint publications

Howard S Hochster

3 joint publications

Sepideh Gholami

3 joint publications

Erin B Kennedy

2 joint publications

Hagen Kennecke